I recently co-authored an eight-part review of the clinical literature on psychedelics, which was published as a special edition of The American Journal of Therapeutics in March 2024. The review is written for an audience of primary care physicians, but it should be accessible for everybody. All eight parts are now published, with links below. In October 2025, I also co-authored a new review paper on 5-MeO-DMT, which is currently available as a pre-print (also below).

1. Historical Perspective and Overview (Introduction)
2. LSD
3. DMT and Ayahuasca
4. Psilocybin
5. Ibogaine
6. MDMA
7. Ketamine
8. The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics (Conclusion)
9. 5-MeO-DMT (NEW)